Aptevo Therapeutics (FRA:AP82) Long-Term Debt: €0.00 Mil (As of Mar. 2026)


FRA:AP82 Aptevo Therapeutics Inc FRA:AP82
29 GF Score
Price €65,970.00
! 1 Warning Sign
View Full Analysis

What is Aptevo Therapeutics Long-Term Debt?

Aptevo Therapeutics FRA:AP82 29 Long-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:AP82 with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Aptevo Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was €0.00 Mil.

Aptevo Therapeutics  (FRA:AP82) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Aptevo Therapeutics Long-Term Debt Related Terms

Aptevo Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Aptevo Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aptevo Therapeutics Long-Term Debt Chart

Aptevo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.28 1.37 0.00 0.00 0.00

Aptevo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:AP82
29GF Score
Aptevo Therapeutics Inc FRA:AP82
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Aptevo Therapeutics (FRA:AP82) has a Long-Term Debt of €0.00 Mil as of Mar. 2026.
Is Aptevo Therapeutics' Long-Term Debt too high?
Aptevo Therapeutics' current Long-Term Debt is €0.00 Mil. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Long-Term Debt compare to ENVB and ADIL?
Aptevo Therapeutics' Long-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Aptevo Therapeutics's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (FRA:AP82) has a current Long-Term Debt of €0.00 Mil. The current Long-Term Debt is €0.00 Mil. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Aptevo Therapeutics (FRA:AP82), the current Long-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptevo Therapeutics Business Description

Other Exchanges APVO:USA
Address 2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score

Get the complete analysis for FRA:AP82

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65,970.00
Price